Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older.